result
SPOTLIGHT
COVID-19
News
Find the most recent news about COVID-19 research conducted by our clinician scientists, researchers, innovators and faculty.
Gov Abbott visit
Gov. Abbott Visits Houston Methodist
January 19, 2021 - Texas Gov. Greg Abbott acknowledged Houston Methodist's efforts throughout the pandemic, including our role as one of 28 state hubs to help vaccinate the public. We also were the first hospital in the country to use convalescent plasma and have conducted numerous clinical trials for newly developed treatments. We have administered such a high volume of monoclonal antibody treatments that we now order directly from the distributor.
Farhaan Vahidy PhD MBBS MPH
Study Indicates Men More Susceptible to COVID-19
January 13, 2021 - PLoS One published a study led by Farhaan Vahidy, PhD, at Houston Methodist's Center for Outcomes Research, showing that males are more likely to test positive for COVID-19, have complications and die from the virus than females, independent of age.
COVID-19 REGN-CoV2 Clinical Trial
October 2, 2020 - Medical director of critical care Faisal Masud, MD, and Houston Methodist Research Institute president and CEO Ed Jones are quoted in a
Houston Chronicle
front page story about recent COVID-19 treatments, including the use of an antibody cocktail,
REGN-CoV2, currently in a clinical trial at Houston Methodist
.
Learning Health Care System Takes on COVID-19
September 14, 2020 - The CURATOR digital repository brought rapid access to data comparing differences between Houston’s first and second surges, allowing Houston Methodist to quickly adapt treatment plans.
Plasma Therapy Proves Transformative
August 14, 2020 - The first to receive FDA approval to offer convalescent plasma therapy—and the first to publish study results—Houston Methodist is leading medical research on treatments for COVID-19. For this Houston patient, the decision to participate in the research trial made all the difference.
COVID-19 Brings Awareness of Health Disparities
August 4, 2020 - The pandemic is bringing a new awareness of the social determinants of health—and possibly a new population health data set that reveals more about health inequities. Director of the Center for Outcomes Research Bita Kash, PhD, discusses the effects on hospital-community partnerships.
Antiviral Offers Outpatient Treatment Option
July 27, 2020 -
An antiviral drug, favipiravir, previously approved in Japan to treat influenza, is now under clinical investigation at Houston Methodist to treat the SARS-CoV-2 coronavirus. The Phase 2, multicenter, randomized trial is sponsored by Fujifilm Pharmaceuticals U.S.A., Inc.
Facing the Unseen Crisis: Health Provider Burnout
July 20, 2020 -
During the initial peak of COVID-19, Houston Methodist researchers shared their expertise on ICU staff burnout in a study on "Provider Burnout and Fatigue during the COVID-19 Pandemic: Lessons Learned from a High-Volume Intensive Care Unit." Published in April, it remains among Altmetric's most popular publications.
Wong Participates in COVID-19 Consortium
July 10, 2020 -
Stephen T. Wong, PhD, John S. Dunn, Sr. Presidential Distinguished Chair in Biomedical Engineering, participated in an international COVID-19 consortium established to mine shared, secured information from COVID-19 patients across multiple institutions in the U.S., Europe, Middle East and Africa. Oxford University Press published an article in the
Journal of the American Medical Informatics Association
.
FDA Fast-Tracks RLF-100 Trial for Treating ARDS
June 24, 2020 -
Jihad Georges Youssef, MD
, professor of clinical medicine, Department of Medicine, and transplant pulmonologist, J.C. Walter Jr. Transplant Center, is leading a multi-center clinical trial fast-tracked by the FDA to test a treatment for acute lung injury and, specifically, acute respiratory distress syndrome (ARDS) associated with COVID-19.
Remdesivir Proves Promising
April 16, 2020 - Early results encourage the clinical research team conducting clinical trials of Gilead Sciences’ antiviral drug Remdesivir. Methodist Hospital was the first clinical trial site in Houston to test the antiviral drug.
Helmet May Help COVID-19 Patients Avoid Intubation
April 14, 2020 - The most severe COVID-19 patients may require intubation, which can put health care providers at risk. When seeking clinical alternatives to intubation, the innovative "helmet" offers a promising option.
EnMed Produces an N95 Alternative
March 26, 2020 - As cases of COVID-19 increased and the nation put out a call for PPE, Houston Methodist worked with its engineering partners at Texas A&M University to create a 3D-printed alternative to conventional N95 masks.
GeneOne Life Science and Houston Methodist to Develop a COVID-19 Vaccine
March 17, 2020 - Houston Methodist researchers are partnering with GeneOne Life Science Inc. to develop an RNA vaccine against COVID-19, the novel coronavirus that has caused a global pandemic.
Sign up for our monthly newsletter.
Sign Up
Copyright 2020. Houston Methodist, Houston, TX. All rights reserved.
Privacy & Disclaimer
|
Sign Up for Our Monthly Newsletter
|
Browse the Archive
FOLLOW US